1. In Vivo
  2. >>Business Strategy

Progress in Cervical Cancer Screening

The smoke from the Pap wars is beginning to clear as Cytyc, which sells the {ThinPrep} monolayer system for screening for cervical cancer pushes ahead and NeoPath gets FDA approval to sell its automated instrument as a primary reader of Pap smears. Cytyc is doing quite well in its battle to get attractive reimbursement for its sample prep method. More problematic is NeuroMed Systems, which is struggling to maintain the interest of laboratories in its device which helps pathologists pinpoint trouble spots on Pap smears.

The smoke from the Pap wars is beginning to clear. Of the three companies with FDA-cleared approaches to cervical cancer screening, Cytyc Corp. 's gamble seems to be paying off best. NeoPath Inc. continues to fit into the "promising but not quite certain" category and the prognosis for Neuromedical Systems Inc. is poor. Two developments this month indicated just how far the situation has come.

First, Cytyc and Dianon Systems Inc. , an anatomic pathology laboratory (see"Consolidation in Diagnostics: AmeriPath vs. Dianon," IN VIVO,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Can Kennedy’s Crackdown Really Dismantle Big Pharma’s Ad Machine?

 
• By Ed Silverman

For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.

Digital Twins Grow Up But Adoption Hurdles Remain

 
• By David Wild

Early commercial successes are proving the value of digital twins, yet regulatory uncertainty and cultural resistance continue to limit widespread uptake across biopharma.

Could A New ‘Impact’ Measure Attract More Capital To Biotech?

 
• By Melanie Senior

The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.

Q&A: FDA’s AI Push Creates Imperative for ‘AI-Ready’ Drug Discovery Data

 
• By David Wild

Charles River's chief scientific officer Julie Frearson discusses how the agency's embrace of artificial intelligence is driving a fundamental shift in how companies must structure and manage their research data

More from In Vivo

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Deals In Depth: August 2025

 
• By Deanna Kamienski and Maureen Riordan

Seven $1bn+ alliances were penned in August, and two exceeded $2bn.

As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates

 
• By David Wild

With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.